Halozyme Therapeutics (NASDAQ:HALO) Stock Rating Lowered by BidaskClub

Halozyme Therapeutics (NASDAQ:HALO) was downgraded by stock analysts at BidaskClub from a “buy” rating to a “hold” rating in a research note issued to investors on Friday, BidAskClub reports.

Other analysts also recently issued research reports about the stock. ValuEngine upgraded shares of Zogenix from a “buy” rating to a “strong-buy” rating in a report on Thursday, June 27th. Zacks Investment Research downgraded shares of ExlService from a “hold” rating to a “sell” rating in a report on Wednesday. Finally, Cantor Fitzgerald began coverage on shares of Veru in a report on Monday, July 1st. They set an “overweight” rating and a $6.00 price objective for the company. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and three have assigned a buy rating to the company. The company presently has an average rating of “Hold” and a consensus target price of $21.00.

NASDAQ HALO opened at $16.58 on Friday. Halozyme Therapeutics has a 52-week low of $13.24 and a 52-week high of $18.85. The stock’s 50-day moving average is $16.15. The company has a debt-to-equity ratio of 0.07, a current ratio of 2.95 and a quick ratio of 2.72.



Halozyme Therapeutics (NASDAQ:HALO) last posted its quarterly earnings data on Tuesday, May 7th. The biopharmaceutical company reported $0.01 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $0.01. Halozyme Therapeutics had a negative net margin of 28.70% and a negative return on equity of 20.36%. The business had revenue of $56.95 million during the quarter, compared to the consensus estimate of $67.80 million. During the same quarter last year, the company posted ($0.19) earnings per share. The firm’s quarterly revenue was up 84.3% compared to the same quarter last year. On average, equities research analysts anticipate that Halozyme Therapeutics will post -0.42 EPS for the current year.

Large investors have recently modified their holdings of the business. Sageworth Trust Co boosted its position in Halozyme Therapeutics by 4,200.0% during the first quarter. Sageworth Trust Co now owns 2,150 shares of the biopharmaceutical company’s stock worth $35,000 after purchasing an additional 2,100 shares during the period. Amundi Pioneer Asset Management Inc. bought a new position in Halozyme Therapeutics during the fourth quarter worth about $140,000. Pathlight Investors LLC bought a new position in Halozyme Therapeutics during the fourth quarter worth about $151,000. Paloma Partners Management Co bought a new position in Halozyme Therapeutics during the fourth quarter worth about $150,000. Finally, Hsbc Holdings PLC bought a new position in Halozyme Therapeutics during the fourth quarter worth about $157,000. Hedge funds and other institutional investors own 82.07% of the company’s stock.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc, a biotechnology company, engages in researching, developing, and commercializing novel oncology therapies in the United States, Switzerland, and internationally. Its human enzymes are used to facilitate the delivery of injected drugs and fluids, enhancing the efficacy and the convenience of other drugs or can be used to alter tissue structures for clinical benefit.

Recommended Story: What is a conference call?

Receive News & Ratings for Halozyme Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Halozyme Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.